Chemokine receptor antagonists: A new era of HIV therapy?

被引：3

作者：

Julg, B ^{[1
]}

Goebel, FD ^{[1
]}

机构：

[1] Univ Munich, Dept Infect Dis, Med Poliklin, D-80336 Munich, Germany

来源：

INFECTION | 2005年 / 33卷 / 5-6期

关键词：

D O I：

10.1007/s15010-005-6605-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Chemokine receptors are essential for human immunodeficiency virus (HIV) cell entry. CXCR4 and CCR5 are the two most relevant receptors and by inhibition of each of them a delayed onset of disease could be achieved. As both receptors are used at different stages of disease due to the domination of different HIV strains, a dual blockage of CXCR4 and CCR5 could be highly valuable for inhibiting viral transmission and replication.

引用

页码：408 / 410

页数：3

共 23 条

[1] Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects [J].

Adkison, KK ;

Shachoy-Clark, A ;

Fang, L ;

Lou, Y ;

O'Mara, K ;

Berrey, MM ;

Piscitelli, SC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :2802-2806

[2] CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].

Alkhatib, G ;

Combadiere, C ;

Broder, CC ;

Feng, Y ;

Kennedy, PE ;

Murphy, PM ;

Berger, EA .

SCIENCE, 1996, 272 (5270) :1955-1958

[3] HIV blocked by chemokine antagonist [J].

ArenzanaSeisdedos, F ;

Virelizier, JL ;

Rousset, D ;

ClarkLewis, I ;

Loetscher, P ;

Moser, B ;

Baggiolini, M .

NATURE, 1996, 383 (6599) :400-400

[4] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].

Baba, M ;

Nishimura, O ;

Kanzaki, N ;

Okamoto, M ;

Sawada, H ;

Iizawa, Y ;

Shiraishi, M ;

Aramaki, Y ;

Okonogi, K ;

Ogawa, Y ;

Meguro, K ;

Fujino, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703

[5] A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains [J].

Berson, JF ;

Long, D ;

Doranz, BJ ;

Rucker, J ;

Jirik, FR ;

Doms, RW .

JOURNAL OF VIROLOGY, 1996, 70 (09) :6288-6295

[6] The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C [J].

Cilliers, T ;

Nhlapo, J ;

Coetzer, M ;

Orlovic, D ;

Ketas, T ;

Olson, WC ;

Moore, JP ;

Trkola, A ;

Morris, L .

JOURNAL OF VIROLOGY, 2003, 77 (07) :4449-4456

[7] IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].

COCCHI, F ;

DEVICO, AL ;

GARZINODEMO, A ;

ARYA, SK ;

GALLO, RC ;

LUSSO, P .

SCIENCE, 1995, 270 (5243) :1811-1815

[8] Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].

Connor, RI ;

Sheridan, KE ;

Ceradini, D ;

Choe, S ;

Landau, NR .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628

[9] Identification of a major co-receptor for primary isolates of HIV-1 [J].

Deng, HK ;

Liu, R ;

Ellmeier, W ;

Choe, S ;

Unutmaz, D ;

Burkhart, M ;

DiMarzio, P ;

Marmon, S ;

Sutton, RE ;

Hill, CM ;

Davis, CB ;

Peiper, SC ;

Schall, TJ ;

Littman, DR ;

Landau, NR .

NATURE, 1996, 381 (6584) :661-666

[10] AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor [J].

Donzella, GA ;

Schols, D ;

Lin, SW ;

Esté, JA ;

Nagashima, KA ;

Maddon, PJ ;

Allaway, GP ;

Sakmar, TP ;

Henson, G ;

De Clercq, E ;

Moore, JP .

NATURE MEDICINE, 1998, 4 (01) :72-77

← 1 2 3 →